Related Experiment Video
Updated: May 8, 2026
Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery/design in
Louise J Gourlay1, Claudio Peri, Mario Ferrer-Navarro
1Department of Biosciences, University of Milan, 20133 Milan, Italy.
Abstract:
We solved the crystal structure of Burkholderia pseudomallei acute phase antigen BPSL2765 in the context of a structural vaccinology study, in the area of melioidosis vaccine development. Based on the structure, we applied a recently developed method for epitope design that combines computational epitope predictions with in vitro mapping experiments and successfully identified a consensus sequence within the antigen that, when engineered as a synthetic peptide, was selectively immunorecognized to the same extent as the recombinant protein in sera from melioidosis-affected subjects. Antibodies raised against the consensus peptide were successfully tested in opsonization bacterial killing experiments and antibody-dependent agglutination tests of B. pseudomallei. Our strategy represents a step in the development of immunodiagnostics, in the production of specific antibodies and in the optimization of antigens for vaccine development, starting from structural and physicochemical principles.
Insights
Researchers developed a novel melioidosis vaccine strategy by identifying a key antigen's structure. This led to a synthetic peptide that effectively elicits an immune response, aiding vaccine and diagnostic development.
Area of Science:
- Structural vaccinology
- Melioidosis vaccine development
- Immunoinformatics
Background:
- Melioidosis is a serious infectious disease caused by Burkholderia pseudomallei.
- Current vaccine strategies require optimization for broader efficacy.
Purpose of the Study:
- To determine the crystal structure of Burkholderia pseudomallei acute phase antigen BPSL2765.
- To develop a novel vaccine candidate based on structural and immunological data.
- To identify and synthesize a potent BPSL2765-derived epitope for diagnostic and therapeutic applications.
Main Methods:
- X-ray crystallography to solve the BPSL2765 structure.
- Computational epitope prediction algorithms.
- In vitro B cell epitope mapping.
- Synthetic peptide synthesis and immunological testing.
- Opsonization assays and antibody-dependent bacterial killing.
Main Results:
- The crystal structure of BPSL2765 was elucidated.
- A consensus epitope sequence was identified and synthesized.
- The synthetic peptide demonstrated equivalent immunorecognition to the native antigen in patient sera.
- Antibodies against the peptide showed efficacy in bacterial killing and agglutination assays.
Conclusions:
- Structural vaccinology approach successfully identified a potent BPSL2765 epitope.
- The synthetic peptide is a promising candidate for melioidosis immunodiagnostics and vaccine development.
- This strategy advances antigen optimization using structural and physicochemical principles.
More Related Videos
22:10Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
Published on: June 28, 2013
13:53Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
